Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism.

[1]  Guy Meyer,et al.  Management of Pulmonary Embolism: An Update. , 2016, Journal of the American College of Cardiology.

[2]  J. Vachiéry,et al.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.

[3]  R. Yusen,et al.  Trends in the Management and Outcomes of Acute Pulmonary Embolism: Analysis From the RIETE Registry. , 2016, Journal of the American College of Cardiology.

[4]  S. Konstantinides.  Trends in incidence versus case fatality rates of pulmonary embolism: Good news or bad news? , 2015, Thrombosis and Haemostasis.

[5]  Nicolas Meneveau,et al.  Erratum: 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism (European Heart Journal (2014) 35 (3033-73) DOI 10.1093/eurheartj/ehu283) , 2015 .

[6]  F. Pomero,et al.  Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy , 2015, Thrombosis and Haemostasis.

[7]  D. Jiménez,et al.  Trends in hospital admissions for pulmonary embolism in Spain from 2002 to 2011 , 2014, European Respiratory Journal.

[8]  C. Combescure,et al.  Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis , 2014, European heart journal.

[9]  M. Revel,et al.  Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism , 2014, Thrombosis and Haemostasis.

[10]  M. Sebbane,et al.  Fibrinolysis for patients with intermediate-risk pulmonary embolism. , 2014, The New England journal of medicine.

[11]  J. Kline,et al.  Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double‐blind, placebo‐controlled randomized trial , 2014, Journal of thrombosis and haemostasis : JTH.

[12]  M. Sharifi,et al.  Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial). , 2013, The American journal of cardiology.

[13]  Elie A Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[14]  Lisa M. Schwartz,et al.  Time trends in pulmonary embolism in the United States: evidence of overdiagnosis. , 2010, Archives of internal medicine.

[15]  J. Landy,et al.  Trends in hospital admissions for pulmonary embolism. , 2008, Clinical medicine.

[16]  J. Kline,et al.  Echocardiographic and functional cardiopulmonary problems 6 months after first-time pulmonary embolism in previously healthy patients. , 2007, European heart journal.

[17]  L. Kritharides,et al.  Natural history of right ventricular dysfunction after acute pulmonary embolism. , 2007, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[18]  Paolo Prandoni,et al.  Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. , 2004, The New England journal of medicine.

[19]  A. Alavi,et al.  The clinical course of pulmonary embolism. , 1992, The New England journal of medicine.

[20]  Jeroen J. Bax,et al.  ESC Guidelines on the diagnosis and management of acute pulmonary embolism , 2014 .

[21]  M. Humbert,et al.  The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS) , 2014 .

[22]  Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. , 2012, American heart journal.

[23]  G. Filippatos,et al.  Guidelines for the diagnosis and treatment of pulmonary hypertension , 2009 .

[24]  Piotr Pruszczyk,et al.  Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism , 2008 .